Wheat straw was liquefied in the mixture of polyethylene glycol (PEG 400) and glycerin in the presence of acid at the temperature 130-160 C. The final liquefaction products having the hydroxyl number of 250-430 mg KOH/g and the M n of about 1050 can be used as the polyol component to manufacture polyurethane. A kind of polyurethane foam was prepared from liquefied wheat straw, commercial polyol, and diisocyanates in the presence of organotin catalysts and foaming agents. The polyurethane foam presented better compressive strength and thermal stability than that manufactured from diisocyanate and polyol alone. The thermal stability of PU foam was improved with the increase of [NCO]/[OH] ratio and the addition of liquefied wheat straw. The polyurethane foam presented faster biodegradation at ambient temperature than normal polyurethane foam did.

Buruli ulcer (BU) is an emerging infectious disease that causes disfiguring skin ulcers. The causative agent, Mycobacterium ulcerans, secretes toxin called mycolactone that triggers inflammation and immunopathology. Existing treatments are lengthy and consist of drugs developed for tuberculosis. Here, we report that a pyrazolo[1,5-a]pyridine-3-carboxamide, TB47, is highly bactericidal against M. ulcerans both in vitro and in vivo. In the validated mouse model of BU, TB47 alone reduces M. ulcerans burden in mouse footpads by more than 2.5 log10 CFU compared to the standard BU treatment regimen recommended by the WHO. We show that mutations of ubiquinol-cytochrome C reductase cytochrome subunit B confer resistance to TB47 and the dissimilarity of CydABs from different mycobacteria may account for their differences in susceptibility to TB47. TB47 is highly potent against M. ulcerans and possesses desirable pharmacological attributes and low toxicity that warrant further assessment of this agent for treatment of BU.